On 10 February 2010, the shares of Scandinavian Tobacco Group (“STG”) were admitted for trading on NASDAQ Copenhagen. Kromann Reumert served as legal adviser to STG and the selling shareholders, the Augustinus Foundation, the Obel Family Foundation and Swedish Match AB, on the IPO
Scandinavian Tobacco Group (originally Skandinavisk Tobakskompagni) is one of the world's leading manufacturers of cigars and traditional pipe tobacco, employing more than 8,100 employees around the globe.

Stephenson Harwood LLP has advised Phoenix Spree Deutschland Limited (the "Company") on a secondary fundraising by way of a firm placing, offer for subscription and placing programme. The Company is targeting an initial issue of £38 million and also intends to implement a placing programme to enable it to raise capital in an efficient and cost-effective manner over the next 12 months. Stephenson Harwood advised on all aspects of the fundraising.

Stephenson Harwood LLP has advised Miton UK MicroCap Trust plc (the "Company") on a proposed issue of C shares by way of a placing, offer for subscription and intermediaries offer together with a placing programme.

The Firm is advising Ascential plc, a portfolio company of funds advised by Apax Partners, in its initial primary offering and admission to the Official List in the UK and to trading on the London Stock Exchange, expected to occur on February 12, 2016. Ascential is an international, business-to-business media company with a focused portfolio of essential, market leading events and information services products that connect and inform business professionals.

B.R.A.I.N. Biotechnology Research and Information Network AG (“BRAIN AG”), Zwingenberg, successfully completed its IPO with the initial listing of its shares on the Frankfurt Stock Exchange on 9 February 2016. The total issue volume was €31.5m. A total of 3,500,000 shares resulting from a capital increase were placed in the context of the offering. In addition, the hitherto majority shareholder of the company made available 108,054 of its shares as part of an over-allotment option for market stabilisation reasons.

Charles Russell Speechlys’ Advisory team recently acted as the legal adviser to Chelverton Growth Trust plc (the Company) on its Court approved reduction of capital and its latest tender offer, which was announced on 3 February 2016.

The tender offer is the latest in a series of tender offers by the Company to achieve its strategy of returning capital to shareholders.

The Charles Russell Speechlys team advising on this transaction was led by Partner Andrew Collins and included Corporate Associate Emily Davies.

KWM has been lead legal adviser to NAB on its demerger and cross-border IPO of CYBG PLC, which was successfully completed last night.

The successful conclusion of the demerger and IPO of CYBG is a significant milestone for NAB that will enable it to pursue its focused strategy in its core markets in Australia and New Zealand.

CYBG PLC is listed on both the Australian Securities Exchange and London Stock Exchange and has a market capitalisation of approximately AU$3.2billion.

White & Case LLP has advised CGG, a fully integrated geoscience company, on its €350 million rights issue.

The rights issue is part of CGG's transformation plan and the net proceeds will be used to reinforce its shareholders' equity.

Bpifrance and IFP Energies Nouvelles, which hold together 10.62 percent of CGG's share capital, undertook together to exercise all their rights.

Paris, February 2 2016 – Jeantet is acting as legal adviser of Nippon Steel Sumitomo Metal Corporation in Vallourec’s plan to raise 1 billion euros.

Specialist medtech company Angle announced plans to raise funds via a firm placing of new ordinary shares with existing institutional investors as well as three new major institutional investors. The fundraising will facilitate the commercialisation of its patented Parsortix liquid biopsy system which has the potential to transform the diagnosis and treatment of cancer by making it possible to harvest intact cancer cells from patient blood for analysis.